Mesoblast (NASDAQ:MESO) Shares Gap Down – Time to Sell?

Mesoblast Limited (NASDAQ:MESO)’s stock price gapped down before the market opened on Wednesday . The stock had previously closed at $20.40, but opened at $19.08. Mesoblast shares last traded at $18.84, with a volume of 62,399 shares.

Analysts Set New Price Targets

A number of brokerages recently issued reports on MESO. Cantor Fitzgerald raised Mesoblast to a “strong-buy” rating in a research report on Thursday, January 30th. Piper Sandler increased their price target on Mesoblast from $11.00 to $15.00 and gave the stock an “overweight” rating in a research report on Thursday, December 19th. Finally, Jefferies Financial Group downgraded Mesoblast from a “buy” rating to a “hold” rating in a research report on Monday, December 23rd. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $13.50.

Mesoblast Stock Performance

The stock has a fifty day simple moving average of $16.04 and a two-hundred day simple moving average of $10.81. The company has a quick ratio of 1.18, a current ratio of 1.18 and a debt-to-equity ratio of 0.21.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of MESO. Strategic Financial Concepts LLC bought a new position in Mesoblast during the 4th quarter worth $2,744,000. Jane Street Group LLC raised its position in Mesoblast by 46.4% during the 3rd quarter. Jane Street Group LLC now owns 85,102 shares of the company’s stock worth $695,000 after purchasing an additional 26,959 shares during the last quarter. Marshall Wace LLP bought a new position in Mesoblast during the 2nd quarter worth $562,000. XY Capital Ltd bought a new position in Mesoblast during the 3rd quarter worth $244,000. Finally, Pine Valley Investments Ltd Liability Co raised its position in Mesoblast by 78.7% during the 4th quarter. Pine Valley Investments Ltd Liability Co now owns 20,931 shares of the company’s stock worth $414,000 after purchasing an additional 9,217 shares during the last quarter. 1.43% of the stock is currently owned by institutional investors.

About Mesoblast

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.